COMP <GO>
TGTX vs UNH // 10Y YIELD & FRED MACRO BETA
TG Therapeutics Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: TGTX 9
— UNH 6
▲ 10Y YIELD & FRED MACRO BETA LEADER: TGTX
LAST: $61.18 (+5.34%) • MKT CAP: $8.89B
macro-sensitivity
0.87
LAST: $406.97 (-0.96%) • MKT CAP: $364.66B
macro-sensitivity
0.33
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TGTX VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TGTX | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 83.70% | 88.57% | -4.87 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 12.00% | 11.47% | +0.53 | TGTX | /roic <GO> |
| EV/EBITDA & P/E Valuation | 73.3x | 16.4x | +56.85 | UNH | /valuation <GO> |
| Free Cash Flow Yield | -0.28% | 6.48% | -6.76 | UNH | /fcf-yield <GO> |
| Operating Margin | 20.00% | 4.82% | +15.18 | TGTX | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 3.14% | +64.86 | TGTX | /net-margins <GO> |
| Revenue Growth (YoY) | 87.30% | 6.46% | +80.84 | TGTX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 12.92 | 3.12 | +9.80 | TGTX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 6.74% | -0.24 | TGTX | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 69.7 | 56.0 | +13.66 | TGTX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 0.87 | 0.33 | +0.54 | TGTX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 16.7x | 17.1x | -0.39 | TGTX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $8.89B | $364.66B | -$355.77B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TGTX REV | UNH REV | TGTX GROSS % | UNH GROSS % | TGTX FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $616.3M | $447.57B | 83.7% | 88.7% | -$25.0M | $16.07B |
| FY 2024 | $329.0M | $400.28B | 88.3% | 88.3% | -$40.6M | $20.70B |
| FY 2023 | $233.7M | $371.62B | 44.0% | 89.6% | -$41.9M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TGTX // BETA 0.87
UNH // BETA 0.33